文献速递前列腺癌

转移性激素敏感性前列腺癌患者接受雄激素受体信号抑制剂治疗的健康相关生活质量:联合治疗的作用

Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-04-13

系统综述纳入6项III期随机对照试验,评估雄激素受体信号抑制剂(ARSI)联合雄激素剥夺治疗(ADT)对转移性激素敏感性前列腺癌(mHSPC)患者健康相关生活质量(HR-QoL)的影响。恩扎卢胺或醋酸阿比特龙联合泼尼松加ADT较ADT单药、ADT联合第一代非甾体抗雄激素或ADT联合多西他赛提高总体HR-QoL;阿帕他胺和达罗他胺联合ADT分别与ADT单药或ADT联合多西他赛维持相似HR-QoL。恩扎卢胺、醋酸阿比特龙或达罗他胺联合治疗延长至首次疼痛恶化时间,阿帕他胺未延长。

要点

  • 恩扎卢胺或醋酸阿比特龙联合泼尼松加ADT较ADT单药、ADT联合第一代非甾体抗雄激素或ADT联合多西他赛提高总体HR-QoL。
  • 阿帕他胺联合ADT与ADT单药、达罗他胺联合ADT与ADT联合多西他赛分别维持相似HR-QoL。
  • 恩扎卢胺、醋酸阿比特龙或达罗他胺联合治疗延长至首次疼痛恶化时间,阿帕他胺未延长。

核心结论

  • 在mHSPC中,ADT联合ARSI较ADT单药、ADT联合第一代非甾体抗雄激素或ADT联合多西他赛倾向于提高总体HR-QoL并延长至首次疼痛/疲劳恶化时间。
  • ARSI与其余HR-QoL域存在复杂交互作用。
  • 作者主张标准化HR-QoL测量与报告以利于进一步比较。

研究设计与样本

  • 系统综述,检索PubMed/EMBASE、Web of Science、SCOPUS和Cochrane图书馆2011年1月至2022年4月发表的文献。
  • 仅纳入根据PRISMA指南筛选的III期随机对照试验(RCT),共6项。
  • 评估采用经验证的患者报告结局工具测定的HR-QoL差异,包括全局评分及性功能、泌尿症状、肠道症状、疼痛/疲劳、情绪和社会/家庭健康等子域,数据描述性报告。

主要发现

  • 纳入6项RCT:ARCHES和ENZAMET使用恩扎卢胺联合ADT;TITAN使用阿帕他胺联合ADT;STAMPEDE和LATITUDE使用醋酸阿比特龙联合泼尼松(AAP)加ADT;ARASENS使用达罗他胺联合ADT。
  • 恩扎卢胺或AAP联合ADT较ADT单药、ADT联合第一代非甾体抗雄激素或ADT联合多西他赛提高总体HR-QoL。
  • 阿帕他胺联合ADT与ADT单药、达罗他胺联合ADT与ADT联合多西他赛分别维持相似HR-QoL。
  • 恩扎卢胺、AAP或达罗他胺联合治疗延长至首次疼痛恶化时间,阿帕他胺未延长。
  • ADT联合ARSI较ADT单药未报告情绪健康恶化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While the addition of androgen receptor signaling inhibitors (ARSIs) to androgen deprivation therapy (ADT) results in better of overall survival in patients with metastatic hormone-sensitive prostate cancer (mHSPC), information regarding health related quality of life (HR-QoL) is sparse. We aimed at summarizing current evidence on the impact of ARSIs on HR-QoL. METHODS: We performed a systematic review of the published literature on PubMed/EMBASE, Web of Science, SCOPUS, and the Cochrane libraries between January 2011 and April 2022. We included only phase III randomized controlled trials (RCT), which were selected according to the PRISMA guidelines. We aimed at evaluating differences in HR-QoL, assessed by validated patient reported outcomes instruments. We analyzed global scores and sub-domains such as sexual functioning, urinary symptoms, bowel symptoms, pain/fatigue, emotional and social/family wellbeing. We reported data descriptively. RESULTS: Six RCTs were included: two used enzalutamide with ADT as intervention arms (ARCHES, ENZAMET); one used apalutamide with ADT (TITAN); two abiraterone acetate and prednisone (AAP) with ADT (STAMPEDE, LATITUDE); and one darolutamide with ADT (ARASENS). Enzalutamide or AAP with ADT increase overall HR-QoL in comparison with ADT alone, ADT with first generation nonsteroideal anti-androgens or ADT with docetaxel, whereas apalutamide and darolutamide with ADT maintain HR-QoL similarly to ADT alone or ADT with docetaxel, respectively. Time to first deterioration of pain was longer with combination therapy with enzalutamide, AAP or darolutamide, but not with apalutamide. No worsening of emotional wellbeing was reported from the addition of ARSIs to ADT than ADT alone. CONCLUSIONS: The addition of ARSIs to ADT in mHSPC tends to increase overall HR-QoL and prolong time to first deterioration of pain/fatigue compared with ADT alone, ADT with first generation nonsteroideal anti-androgens, and ADT with docetaxel. ARSIs show a complex interaction with remaining HR-QoL domains. We advocate a standardization of HR-QoL measurement and reporting to allow further comparisons.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Afferi L, Longoni M, Moschini M, et al. Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy. Prostate Cancer Prostatic Dis. 2023. PMID: 37055663. doi:10.1038/s41391-023-00668-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。